ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
66,982.26
-0.15%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Aquestive Therapeutics Inc (AQST)

  7. Aquestive Therapeutics Inc (AQST) Noticias

AQST

Aquestive Therapeutics (AQST)

Aquestive Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AQST
FechaHoraFuenteTítuloSímboloCompañía
13/05/202412:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AQSTAquestive Therapeutics Inc
09/05/202407:00GlobeNewswire Inc.Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences ConferenceNASDAQ:AQSTAquestive Therapeutics Inc
07/05/202415:23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AQSTAquestive Therapeutics Inc
07/05/202415:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AQSTAquestive Therapeutics Inc
07/05/202415:19GlobeNewswire Inc.Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AQSTAquestive Therapeutics Inc
29/04/202406:00GlobeNewswire Inc.Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual FilmNASDAQ:AQSTAquestive Therapeutics Inc
25/04/202407:00GlobeNewswire Inc.Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ETNASDAQ:AQSTAquestive Therapeutics Inc
12/04/202415:01GlobeNewswire Inc.Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of NeurologyNASDAQ:AQSTAquestive Therapeutics Inc
01/04/202407:00GlobeNewswire Inc.Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech ExecutiveNASDAQ:AQSTAquestive Therapeutics Inc
25/03/202407:00GlobeNewswire Inc.Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common StockNASDAQ:AQSTAquestive Therapeutics Inc
19/03/202420:49GlobeNewswire Inc.Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common StockNASDAQ:AQSTAquestive Therapeutics Inc
19/03/202415:01GlobeNewswire Inc.Aquestive Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:AQSTAquestive Therapeutics Inc
14/03/202416:23GlobeNewswire Inc.Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA MeetingNASDAQ:AQSTAquestive Therapeutics Inc
08/03/202415:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AQSTAquestive Therapeutics Inc
05/03/202416:12Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AQSTAquestive Therapeutics Inc
05/03/202416:05GlobeNewswire Inc.Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AQSTAquestive Therapeutics Inc
21/02/202407:00GlobeNewswire Inc.Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ETNASDAQ:AQSTAquestive Therapeutics Inc
15/02/202407:00GlobeNewswire Inc.Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual MeetingNASDAQ:AQSTAquestive Therapeutics Inc
14/02/202414:24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AQSTAquestive Therapeutics Inc
12/02/202416:02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AQSTAquestive Therapeutics Inc
30/01/202407:00GlobeNewswire Inc.Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare ConferenceNASDAQ:AQSTAquestive Therapeutics Inc
05/12/202307:00GlobeNewswire Inc.Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual FilmNASDAQ:AQSTAquestive Therapeutics Inc
10/11/202307:00GlobeNewswire Inc.Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual MeetingNASDAQ:AQSTAquestive Therapeutics Inc
06/11/202315:37GlobeNewswire Inc.Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AQSTAquestive Therapeutics Inc
02/11/202307:00GlobeNewswire Inc.Aquestive Therapeutics Completes $45 Million Debt RefinancingNASDAQ:AQSTAquestive Therapeutics Inc
31/10/202307:00GlobeNewswire Inc.Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ETNASDAQ:AQSTAquestive Therapeutics Inc
09/10/202307:00GlobeNewswire Inc.Aquestive Therapeutics Provides Business UpdateNASDAQ:AQSTAquestive Therapeutics Inc
02/10/202315:18Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:AQSTAquestive Therapeutics Inc
01/10/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:AQSTAquestive Therapeutics Inc
20/09/202309:57Dow Jones NewsAquestive Therapeutics Shares Rise 12% on Anaphylm Trial TimelineNASDAQ:AQSTAquestive Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AQST

Su Consulta Reciente

BIT
P1KE46
BNP Paribas Issuance
NASDAQ
DRLOE
Doral Financial
LSE
51ER
Hsbc Bk. 35
COIN
RAREEEEETH
USOTC
ELOAF
Emergence Global Enterpr... (CE)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados